Industry leaders highlighted CAR T manufacturing constraints as the next bottleneck for broader patient access, focusing on scaling, automation, vector engineering, and consistency across batches. In interviews, executives argued that near-term access gains will come from improving both ex vivo production and advancing in vivo concepts in parallel. The coverage emphasized operational variability as a key driver of manufacturing risk, noting how cumulative handoffs and manual interventions can introduce deviations. Executives from VIVEbiotech, Terumo Blood and Cell Technologies, and Bracco described a shift from feasibility demonstrations to building systems designed for commercial throughput. Their comments point to process robustness and analytics as decisive factors in cost reduction and reliability—particularly as demand grows and payers scrutinize outcomes and turnaround times.